{"entity":{"id":"psmd4","kind":"target","name":"PSMD4","aka":["proteasome 26S subunit ubiquitin receptor, non-ATPase 4","26S proteasome non-ATPase regulatory subunit 4","S5A","AF-1","Rpn10"],"tldr":"PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.","summary":"Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Talazoparib and Carfilzomib. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.78, genetic association 0.12, clinical 0.99).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9561","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9561"},{"label":"UniProt P55036","url":"https://www.uniprot.org/uniprotkb/P55036/entry"},{"label":"NCBI Gene 5710","url":"https://www.ncbi.nlm.nih.gov/gene/5710"},{"label":"Ensembl ENSG00000159352","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159352"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["multiple-myeloma","colorectal","breast-cancer","non-hodgkin-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PSMD4","role":["drug-target","biomarker"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9561","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9561","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P55036","url":"https://www.uniprot.org/uniprotkb/P55036/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene PSMD4","url":"https://civicdb.org/features/4630","note":"2 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Breast Cancer (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000159352","url":"https://platform.opentargets.org/target/ENSG00000159352/associations","note":"association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: plasma cell myeloma 0.61, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0)"}],"specificity":"broadly-expressed","distribution":"few-types","specificityNote":"Broadly expressed or essential: HPA lists PSMD4 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMD4: RNA low tissue specificity; high antibody staining in 6 normal tissues. Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Colorectal cancer, Breast cancer (all types), Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas PSMD4 tissue","url":"https://www.proteinatlas.org/ENSG00000159352-PSMD4/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000159352 associations","url":"https://platform.opentargets.org/target/ENSG00000159352/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:9561","ensembl":"ENSG00000159352","uniprot":"P55036","entrez":"5710","firstDescribed":1995,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Johansson et al, J. Biol. Chem, 1995, \"Molecular cloning and expression of a pituitary gland protein modulating intestinal fluid secretion\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7657640/","biology":"Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMD4 acts as an ubiquitin receptor subunit through ubiquitin-interacting motifs and selects ubiquitin-conjugates for destruction. Displays a preferred selectivity for longer polyubiquitin chains. Locus 1q21.3 (HGNC).","whereFound":["Multiple myeloma: Open Targets association 0.61 with plasma cell myeloma (MONDO_0009693)","Colorectal cancer: CIViC evidence names this disease","Breast cancer: CIViC evidence names this disease","Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)","Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)"],"targetClass":"other","prevalence":[]},"route":"/targets/psmd4/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}